retatrutide phase 2 obesity trial results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Phase 2 trial results demonstrate

Many patients notice improvements in energy and recovery within the first few weeks, but the cellular marker improvement is dependent on baseline oxidative stress

Bibcode:2006BBRC..339...47K

Bottom Line GLP-1 medications are powerful tools for managing weight and metabolic healthbut theyre not magic pills, and theyre not without nuance

, , ,

Importantly, absolute rate reductions for all effectiveness outcomes were larger with increasing severity of frailty. Researchers conducted a retrospective cohort study of older adults aged at least 65 years diagnosed with type 2 diabetes who initiated an SGLT2 inhibitor, GLP-1 receptor agonist or a DPP-IV inhibitor